Intellia Therapeutics, Inc. Forecast, price target & analysts
Intellia Therapeutics, Inc. Target price 2026 - Analyst rating & recommendation
Intellia Therapeutics, Inc. Classifications & Recommendation
Intellia Therapeutics, Inc. Price Target
| Target Price | $17.34 |
| Price | $12.26 |
| Potential |
41.44%
register free of charge
|
| Number of Estimates | 18 |
|
18 Analysts have issued a price target Intellia Therapeutics, Inc. 2027 .
The average Intellia Therapeutics, Inc. target price is $17.34.
This is
41.44%
register free of charge
$64.05
422.43%
register free of charge
$9.09
25.86%
register free of charge
|
|
| A rating was issued by 24 analysts: 14 Analysts recommend Intellia Therapeutics, Inc. to buy, 7 to hold and 3 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Intellia Therapeutics, Inc. stock has an average upside potential 2027 of
41.44%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 67.67 | 54.78 |
| 16.91% | 19.06% | |
| EBITDA Margin | -637.24% | -793.03% |
| 29.61% | 24.45% | |
| Net Margin | -609.86% | -834.34% |
| 31.99% | 36.81% |
19 Analysts have issued a sales forecast Intellia Therapeutics, Inc. 2026 . The average Intellia Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an Intellia Therapeutics, Inc. EBITDA forecast 2026. The average Intellia Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
19 Intellia Therapeutics, Inc. Analysts have issued a net profit forecast 2026. The average Intellia Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.81 | -3.26 |
| 27.43% | 14.44% | |
| P/E | negative | |
| EV/Sales | 23.37 |
19 Analysts have issued a Intellia Therapeutics, Inc. forecast for earnings per share. The average Intellia Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Intellia Therapeutics, Inc....
Current Intellia Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Wedbush |
Locked
➜
Locked
|
Locked | Sep 09 2026 |
| Citizens |
Locked
➜
Locked
|
Locked | Sep 09 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 09 2026 |
| Citizens |
Locked
➜
Locked
|
Locked | Aug 25 2026 |
| Evercore ISI Group |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| Wolfe Research |
Locked
➜
Locked
|
Locked | Jul 16 2026 |
| Wedbush |
Locked
➜
Locked
|
Locked | Jul 10 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Wedbush:
Locked
➜
Locked
|
Sep 09 2026 |
|
Locked
Citizens:
Locked
➜
Locked
|
Sep 09 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 09 2026 |
|
Locked
Citizens:
Locked
➜
Locked
|
Aug 25 2026 |
|
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
Wolfe Research:
Locked
➜
Locked
|
Jul 16 2026 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Jul 10 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
